Identifying and Solving Top Challenges to Oncology Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. David Rimm and Roy Herbst identify the top challenges in the area of biomarker testing as well as solutions to these challenges, including availability of sufficient tissue for a large number of biomarker assays, the time some biomarker tests require for completion, the need for a tight association of test results with clinical outcomes, and the development of companion diagnostics for certain immunotherapies.
Dr. Steve O’Day believes a treatment’s value incorporates combination of benefits, side-effects, and cost, stating that if the cost is high, we need to make sure the benefits are huge as well.
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the circumstances in which they would use the Breast Cancer IndexSM (BCI) to assist in determining whether to extend the adjuvant therapy of women with breast cancer beyond 5 years.